2020
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
Kurz S, Tarapore R, Odia Y, Butowski N, Koschmann C, Aguilera D, MacDonald T, Lu G, Allen J, Oster W, Mehta M, Chi A, Wen P. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. Journal Of Clinical Oncology 2020, 38: 2563-2563. DOI: 10.1200/jco.2020.38.15_suppl.2563.Peer-Reviewed Original ResearchSingle agent groupSpinal cord tumorsCombination groupCord tumorsPediatric patientsSpinal cordH3 K27M mutationMedian survival time rangesMedian follow-up timePhase I clinical trialPhase II clinical trialK27M mutationSurvival time rangesClinical experienceSpinal cord gliomasFollow-up timeHigh-grade gliomasII clinical trialsDose reductionDRD2 antagonistsMedian ageProlonged survivalAgent groupDiffuse gliomasUnfavorable prognosis
2019
ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM)
Kurz S, Silverman J, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, Zagzag D, Snuderl M, Goldberg J, Chi A. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi9-vi10. PMCID: PMC6847193, DOI: 10.1093/neuonc/noz175.036.Peer-Reviewed Original ResearchIDH-mutant glioblastomasHypofractionated radiationFollow-upMedian follow-up timeCohort of adult patientsEfficacy of avelumabSafety lead-inAnti-PD-L1Dose-limiting toxicityTime of progressionIDH-mutant gliomasIncreased cerebral edemaMedian OSMedian PFSWorsened hemiparesisPhase IIOpen-labelSlow accrualTransaminase elevationAvelumabDiscontinued treatmentSingle-armMulticenter studyTreatment regimenAdult patients